EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy with Natural Killer Cells: Are Intact Cells Required, or Can Their Bio-Lysate Achieve Therapeutic Efficacy?

Hans Klingemann, Himani Chinnapen

Medical – Clinical – Research · 28.02.2026 · 2 (2)

DOI: 10.52106/3069-9088.1018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical – Clinical – Research, online erschienen am 28.02.2026. Verfasst von Hans Klingemann und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Infusion of engineered immune cells has shown some therapeutic efficacy in cancer patients but high costs and in some cases more significant side effects are supporting the need for new approaches. Here we present a perspective on cellular bio-lysate from NK-92 cells. These cells rapidly proliferate and a method to extract their cytotoxic bio-lysate for clinical application has been developed. The bio-lysate has cross- species anti-tumor activity and also provides a durable, vaccine-like effect.

Zitieren

APA

Klingemann, H., & Chinnapen, H. (2026). Immunotherapy with Natural Killer Cells: Are Intact Cells Required, or Can Their Bio-Lysate Achieve Therapeutic Efficacy?. Medical – Clinical – Research, 2(2). https://doi.org/10.52106/3069-9088.1018

Vancouver

Klingemann H, Chinnapen H. Immunotherapy with Natural Killer Cells: Are Intact Cells Required, or Can Their Bio-Lysate Achieve Therapeutic Efficacy?. Medical – Clinical – Research. 2026;2(2). doi:10.52106/3069-9088.1018

BibTeX
@article{Klingemann2026,
  author = {Klingemann, Hans and Chinnapen, Himani},
  title = {Immunotherapy with Natural Killer Cells: Are Intact Cells Required, or Can Their Bio-Lysate Achieve Therapeutic Efficacy?},
  journal = {Medical – Clinical – Research},
  year = {2026},
  volume = {2},
  number = {2},
  doi = {10.52106/3069-9088.1018}
}
Kostenlos starten →